1-8 of 8
Saran Vardhanabhuti
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume

Clinical Trials & Observations
Frederick L. Locke, Olalekan O. Oluwole, John Kuruvilla, Catherine Thieblemont, Franck Morschhauser, Gilles Salles, Steven P. Rowe, Saran Vardhanabhuti, Joshua Winters, Simone Filosto, Christina To, Paul Cheng, Marco Schupp, Ronald Korn, Marie José Kersten
Journal: Blood
Blood (2024) 143 (24): 2464–2473.
https://doi.org/10.1182/blood.2023021620
Published: 2024
Includes: Supplemental data
Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Marie José Kersten, Umar Farooq, Aaron P. Rapoport, Frederick L. Locke, Lori A. Leslie, Armin Ghobadi, David B. Miklos, Caron A. Jacobson, Javier L. Munoz, Patrick B Johnston, Samantha M. Jaglowski, Ian W. Flinn, Tom van Meerten, Miguel-Angel Perales, Peter Vandenberghe, Peter A. Riedell, Kathleen Dorritie, David Szwajcer, Dimitrios Tzachanis, Saran Vardhanabhuti, Linqiu Du, Simone Filosto, Shilpa A. Shahani, Christina To, Jason Westin
Journal: Blood
Blood (2023) 142 (Supplement 1): 1761.
https://doi.org/10.1182/blood-2023-173873
Published: 2023
Journal Articles

Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7

Frederick L. Locke, Olalekan O. Oluwole, John Kuruvilla, Catherine Thieblemont, Franck Morschhauser, Gilles Salles, Steven P Rowe, Saran Vardhanabhuti, Simone Filosto, Christina To, Paul Cheng, Marco Schupp, Ronald Korn, Marie José Kersten
Journal: Blood
Blood (2022) 140 (Supplement 1): 638–640.
https://doi.org/10.1182/blood-2022-158492
Published: 2022
Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Olalekan O. Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, Andre H. Goy, Marie José Kersten, Caron A. Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thieblemont, John Timmerman, Patrick Stiff, Irit Avivi, Dimitrios Tzachanis, Yan Zheng, Saran Vardhanabhuti, Jenny Nater, Rhine R. Shen, Harry Miao, Jenny Kim, Tom van Meerten
Journal: Blood
Blood (2022) 140 (Supplement 1): 10399–10401.
https://doi.org/10.1182/blood-2022-156117
Published: 2022
Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Olalekan O. Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, Andre H. Goy, Marie José Kersten, Caron Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thieblemont, John M. Timmerman, Patrick Stiff, Irit Avivi, Dimitrios Tzachanis, Jenny J. Kim, Yan Zheng, Rhine R. Shen, Saran Vardhanabhuti, Tom Van Meerten
Journal: Blood
Blood (2021) 138 (Supplement 1): 2832.
https://doi.org/10.1182/blood-2021-147403
Published: 2021
Journal Articles

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Clinical Trials & Observations
Ronan T. Swords, Steven Coutre, Michael B. Maris, Joshua F. Zeidner, James M. Foran, Jose Cruz, Harry P. Erba, Jesus G. Berdeja, Wayne Tam, Saran Vardhanabhuti, Iwona Pawlikowska-Dobler, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Bruce J. Dezube, Douglas V. Faller, Michael R. Savona
Journal: Blood
Blood (2018) 131 (13): 1415–1424.
https://doi.org/10.1182/blood-2017-09-805895
Published: 2018
Includes: Supplemental data
Journal Articles

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

Ronan T Swords, MD PhD FRCPI, FRCPath, Steven Coutre, MD, Michael B. Maris, MD, Joshua F. Zeidner, MD, James M. Foran, MD, Jose C. Cruz, MD, Harry P. Erba, MD PhD, Jesus G. Berdeja, MD, Wayne Tam, MD PhD, Saran Vardhanabhuti, PhD, Iwona Dobler, PhD, Hélène M. Faessel, PhD, Ajeeta B. Dash, PhD, Farhad Sedarati, PhD, Bruce J. Dezube, MD, Michael R. Savona, MD
Journal: Blood
Blood (2016) 128 (22): 98.
https://doi.org/10.1182/blood.V128.22.98.98
Published: 2016
Journal Articles

Reduction of Immunosuppression as Initial Therapy for Post-Transplantation Lymphoproliferative Disorder: Analysis of Efficacy, Safety and Prognostic Factors.

Ran Reshef, MD, Saran Vardhanabhuti, MS, Marlise R Luskin, MD, Daniel F Heitjan, PhD, David L Porter, MD, Edward A Stadtmauer, MD, Donald E Tsai, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 103.
https://doi.org/10.1182/blood.V114.22.103.103
Published: 2009